Gritstone to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 07 2021 - 8:00AM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company developing next generation cancer and infectious disease
immunotherapies, today announced that Andrew Allen, M.D., Ph.D.,
co-founder, president and chief executive officer, will present a
company overview at the Goldman Sachs 42nd Annual Global Healthcare
Conference on Thursday, June 10, 2021, at 10:30 a.m. ET.
A webcast will be available within the Investors & Media
section of the Gritstone website at
https://ir.gritstonebio.com/investors/events. An archived replay
will be accessible for 30 days following the event.
About Gritstone Gritstone bio, Inc. (Nasdaq:
GRTS), a clinical-stage biotechnology company, is developing the
next generation of immunotherapies against multiple cancer types
and infectious diseases. Gritstone develops its products by
leveraging two key pillars—first, a proprietary machine
learning-based platform, Gritstone EDGETM, which is designed to
predict antigens that are presented on the surface of cells, such
as tumor or virally-infected cells, that can be seen by the immune
system; and, second, the ability to develop and manufacture potent
immunotherapies utilizing these antigens to potentially drive the
patient’s immune system to specifically attack and destroy
disease-causing cells. The company’s lead oncology programs include
an individualized neoantigen-based immunotherapy, GRANITE, and an
“off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which
are being evaluated in clinical studies. Within its infectious
disease pipeline, Gritstone is advancing CORAL, a COVID-19 program
to develop a second-generation vaccine, with support from
departments within the National Institutes of Health (NIH), the
Bill & Melinda Gates Foundation, as well as a license agreement
with La Jolla Institute for Immunology. Additionally, the company
has a global collaboration for the development of a therapeutic HIV
vaccine with Gilead Sciences. For more information, please visit
gritstonebio.com.
ContactsMedia:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Investors:Alexandra Santos Wheelhouse Life Science Advisors(510)
871-6161asantos@wheelhouselsa.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Apr 2023 to Apr 2024